The article reports on the announcement of Janssen Biotech Inc., a Johnson & Johnson company, that it would license a gut microbe cocktail developed by Boston-based Vedanta Biosciences, for treating intestinal bowel disease (IBD). The deal is the largest yet announced in the microbiome space. However, Janssen is also developing gut microbiota not whole organisms, but small molecules.